No abstract

No abstract

No abstract

No abstract

Contents Cats are animals with highly efficient reproduction, clearly pointing to a need for suppression of fertility. Although surgical contraception is highly effective, it is not always the method of choice. This is predominantly because it is cost‐intensive, time‐consuming and irreversible, with the latter being of major importance for cat breeders. This article reviews the use of progestins, scleroting agents, immunocontraception, melatonin, GnRH antagonists and finally, GnRH agonists, in adult male and female cats in detail, according to the present state of the art. By now, various scientific and clinical options are available for the suppression of fertility in adult cats and the decision as to which should be chosen – independent of the legal registration of any state – depends on different facts: (i) feral or privately owned animal? (ii) temporary or permanent suppression of fertility wanted/needed? (iii) sex of the animal? New effective and available methods for hormonal contraception include melatonin implants for short‐term post ponement of oestrus in adult queens and slow‐release GnRH‐agonist implants containing deslorelin (Suprelorin®) for short‐ and long‐term contraception in male and female companion and breeding cats.

No abstract

Suppression of oestrus is of major interest in feral cat populations, but also in breeding queens temporarily not intended for breeding. Slow release gonadotropin-releasing hormone (GnRH) agonist implants are a new off-label approach for reproduction control in cats. However, initially, oestrus induction may occur and no data exist regarding what happens if previously mated queens are treated. This case report presents a queen mismated 9 and 8 days before treatment with a 4.7 mg deslorelin implant. The queen delivered four healthy kittens 66 days after mismating, but showed no interest in the kittens and lactation was not adequate. Progesterone and oestradiol concentrations were monitored and the queen was followed until the return of oestrus and subsequent breeding. The next oestrus was observed 498 days after treatment and the queen was mated in the second oestrus afterwards, became pregnant and delivered two healthy kittens, both of which were raised successfully by the queen. This case report clearly shows that pregnancy following a GnRH-agonist implant may go to term, but maternal care might be influenced owing to hormonal changes induced by treatment. In addition, this is the first report demonstrating reversibility of effects induced by long-term treatment with a deslorelin implant (return to oestrus, fertility and normal maternal care).

The aim of this study was to test for the efficacy and safety of the use of aglepristone for pregnancy termination on day 45 in cats. Six healthy cats were treated with 10 mg/kg aglepristone sc on day 45 and 46 after mating; six other cats served as untreated controls. The effect of treatment was monitored by general examination, vaginal cytology, ultrasonography and blood sampling for haematology and progesterone determination. Besides, interoestrus interval and next pregnancy including litter size were recorded. The efficacy of treatment was approximately 67% (4/6) with abortion occurring 4-7 days after the first injection and a sanguineous discharge and erythrocytes in vaginal smears for at least 6 days afterwards. The two treated cats that did not abort gave birth to two kittens on day 67 and had a stillbirth of a single kitten on day 71, respectively. As expected enlargement of the mammary glands and lactation were observed in all treated cats. No other treatment-induced side effects were observed. Progesterone levels at abortion were high (30-140 nmol/l), but were decreased on day 55. Aglepristone treatment did not affect fertility in following cycles. Finally, it can be concluded that late-term pregnancy termination with aglepristone is possible but due to a success rate of 67% an ultrasonographical examination 7 days after treatment is an inherent necessity to control the effect of treatment.